NVLS Nivalis Therapeutics, Inc.

2.35
+0.01  (0%)
Previous Close 2.34
Open 2.35
Price To book 0.74
Market Cap 36.79M
Shares 15,656,000
Volume 56,152
Short Ratio 2.34
Av. Daily Volume 148,931

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released November 28, 2016. Primary endpoint not met.
N91115
Cystic Fibrosis - two copies of the F508del mutation
Phase 2 data released February 24, 2017 - primary endpoint not met.
N91115
Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein